QRxPharma value assed as Actavis deal finalized
Australian company QRxPharma (ASX: QRX) is moving rapidly towards the commercial phase for its lead product, MoxDuo IR, an immediate release fixed-ratio (3:2) combination of morphine and oxycodone for moderate-to-severe pain, note analysts at Edison Investment Research.
The drug is filed in the USA and has a June 25 PDUFA (approval) date. A third-quarter launch is targeted by Actavis, which will commercialize MoxDuo IR in the USA under a deal finalized last week, though first announced last year (The Pharma Letter December 21, 2011), say the Edison analysts. However, they note that speculation that Actavis is subject to a bid by Watson is creating some short-term uncertainty (TPL March 22).
Actavis will spearhead push into US opioid market
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
More Features in Pharmaceutical
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze